Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Advanced In Vivo Imaging Techniques (MRI, PET, BLI) for Monitoring Cell Therapy Engraftment and Efficacy

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Advanced In Vivo Imaging Techniques (MRI, PET, BLI) for Monitoring Cell Therapy Engraftment and Efficacy

Advanced In Vivo Imaging for Cell Therapy Biodistribution and Engraftment

CELL & GENE | RNA | BIOLOGICS

What is the primary advantage of longitudinal in vivo imaging for cell therapies?

Longitudinal imaging enables non-invasive, real-time tracking of cell fate, persistence, and biodistribution within the same subject over an extended period. This approach reduces inter-animal variability and minimizes the total number of animals required for a study, directly supporting the 3Rs principles of animal welfare.

How do you select between Bioluminescence Imaging (BLI), PET, and MRI for a cell therapy study?

The selection is driven by the specific biological question, required sensitivity, and desired resolution.

  • BLI is optimal for high-throughput screening of cell engraftment and tumor burden due to its high sensitivity and rapid acquisition time.

  • PET provides absolute quantification of cell biodistribution and metabolic activity, making it ideal for dose-finding and pharmacokinetic modeling.

  • MRI offers superior anatomical context with high spatial resolution, allowing for precise localization of cells in relation to surrounding tissues.

Can imaging data be correlated with functional outcomes?

Yes. A robust study design integrates imaging with functional assays and terminal histology. Imaging provides the key spatial and temporal data on cell engraftment, which is then directly correlated with functional readouts to build a comprehensive, translatable model of therapeutic efficacy.

Advanced in vivo imaging modalities, including Bioluminescence Imaging (BLI), Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI), provide non-invasive, longitudinal data on cell therapy engraftment, persistence, and biodistribution. This quantitative data is fundamental for de-risking clinical translation by establishing clear relationships between cell location, dose, and therapeutic effect. Franklin Biolabs integrates these techniques with GxP-compliant bioanalysis to generate IND-enabling data packages that withstand rigorous regulatory scrutiny.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

De-Risking Cell Therapy Translation with Quantitative Imaging

Understanding the in vivo fate of a cell therapy product is a primary challenge in preclinical development. Quantifying cell biodistribution, persistence at the target site, and clearance is necessary to build a comprehensive safety and efficacy profile. Non-invasive imaging provides a direct method to visualize and measure these dynamics over time in a single subject, generating a robust dataset that links cellular behavior to therapeutic outcomes.

By generating clear, quantitative evidence of a therapy’s mechanism of action, these studies strengthen the rationale for clinical progression within a typical 18-24 month IND timeline. Our methodology has contributed to a 100% IND success rate for our partners since 2019, a record of execution we bring to the Franklin Biolabs brand, which launched in 2024.

Selecting the Optimal Imaging Modality

Choosing the correct imaging modality is dependent on the specific objectives of the study. Each technique offers a different balance of sensitivity, resolution, and quantitative power. Our scientific team, in collaboration with strategic imaging partners, designs studies that leverage the optimal modality or combination of modalities to address key translational questions.

Modality Principle Spatial Resolution Sensitivity Primary Application
BLI Luciferase enzyme reaction Low (~1-3 mm) High (pico- to femomolar) High-throughput screening, tumor burden
PET Positron-emitting radionuclide Medium (~1-2 mm) High (pico- to nanomolar) Quantitative biodistribution, PK/PD
MRI Nuclear magnetic resonance High (<100 µm) Low (micromolar) Anatomical localization, tissue morphology

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Correlating Imaging with Biological Endpoints

Imaging data provides its greatest value when integrated with other biological endpoints. As demonstrated in gene therapy development (PMID: 35333110), establishing a strong correlation between a therapeutic agent’s biodistribution and its functional effect is a powerful strategy for de-risking a program. We apply this principle by correlating the quantitative signal from PET or the spatial localization from MRI with terminal histology and functional assays. This integrated analysis, conducted within our >100,000 sq ft GxP-compliant facility, confirms that the observed imaging signal corresponds to viable, functional cells and a tangible therapeutic outcome.

Commitment to Animal Welfare and the 3Rs

Longitudinal imaging is a core component of our commitment to the highest standards of animal welfare. By enabling data collection from the same animal over time, these techniques directly support the principles of Reduction and Refinement as defined by our AAALAC and USDA-accredited programs.

*

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities